1. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: Clinical and economic outcomes 
Walter E. Uber, PharmD, John M. Toole, MD, Martha R. Stroud, MS, Jason S. Haney, PharmD, John Lazarchick, MD, Fred A. Crawford, MD, John S. Ikonomidis, MD, PhD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 141, Issue 6, Pages e2 (June 2011)
DOI: /j.jtcvs
Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

2. Figure 1
(A) Comparison of transfusion requirements intraoperatively, (B) postoperatively but before intervention with recombinant activated factor VII (rFVIIa) or reoperation, and (C) after intervention to 24 hours after the primary operation and (D) total blood product use in patients receiving rFVIIa or reoperation for refractory coagulopathy in the intensive care unit. Numbers in parentheses represent multiple patients receiving the specified amount of blood product. Box plots show the median, interquartile range, and minimum and maximum values. RBC, Red blood cells; Reop, reoperation; FFP, fresh frozen plasma.
The Journal of Thoracic and Cardiovascular Surgery  , e2DOI: ( /j.jtcvs )
Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

3. Figure 2
Chest tube output (A) before and after recombinant activated factor VII (rFVIIa) administration and (B) before and after reoperation for refractory coagulopathy in the intensive care unit.
The Journal of Thoracic and Cardiovascular Surgery  , e2DOI: ( /j.jtcvs )
Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions